<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098146</url>
  </required_header>
  <id_info>
    <org_study_id>SMDR_RP_v2.0</org_study_id>
    <nct_id>NCT04098146</nct_id>
  </id_info>
  <brief_title>Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection</brief_title>
  <official_title>International, Multicenter, Prospective Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction (SMDR) Following Oral Squamous Cell Carcinoma (OSSC) Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO Clinical Investigation and Publishing Documentation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO Innovation Translation Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective will be collected in a minimum of 300 patients presenting with an acquired&#xD;
      segmental mandibular defect ≥ 4 cm secondary to OSSC removal and who require mandibular&#xD;
      reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective data will be collected in a minimum of 300 patients presenting with an acquired&#xD;
      segmental mandibular defect ≥ 4 cm secondary to OSSC removal and who require mandibular&#xD;
      reconstruction.&#xD;
&#xD;
      The follow up (FU) will consist of standard of care (routine) procedures and data collection&#xD;
      will be done at 3, 6, 12, 18 and up to 24 months after resection and/or reconstruction. The&#xD;
      maximum FU for each patient within the registry will be 2 years after mandibular resection.&#xD;
&#xD;
      Data collection will include confounding baseline data, tumor characteristics, neurological&#xD;
      function, patient reported outcomes, quality of life as well as anticipated procedure-related&#xD;
      adverse events (AEs). Available images will be collected and evaluated centrally to determine&#xD;
      the location, positioning, osseointegration, bone quantity and quality of the transplants.&#xD;
&#xD;
      Depending on the volume and quality of the collected data, different statistical analyses&#xD;
      will be performed. Exploratory analyses will be conducted to find relationships between the&#xD;
      different treatment modalities and their outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Demographics</measure>
    <time_frame>Baseline until resection surgery approximately 4 weeks</time_frame>
    <description>Demographics (year of birth, height in cm and weight in kilogram, race)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comorbidities</measure>
    <time_frame>Baseline until resection surgery approximately 4 weeks</time_frame>
    <description>Comorbidities assessed by Charlson Comorbidity Index (this score assesses the comorbidity level by considering both the number and severity of predefined comorbidity conditions. It provides a weighted score of a patient's comorbidities which can be used to predict mortality rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nicotine consumption</measure>
    <time_frame>Baseline until resection surgery approximately 4 weeks</time_frame>
    <description>Current and previous nicotine use will be collected:&#xD;
Number of years&#xD;
Time (years) since stopped using (if applicable)&#xD;
Amount of cigarettes/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient reported outcome: Oral Health Impact Profile (OHIP)</measure>
    <time_frame>Baseline/ 3months/ 6 months/ 12 months/ 18 months/ 24 months</time_frame>
    <description>Change in the OHIP over the follow-up period.&#xD;
The Oral Health Impact Profile is providing a comprehensive measure of self-reported dysfunction, discomfort and disability attributed to oral conditions. The OHIP is concerned with impairment and three functional status dimensions (social, psychological, and physical). Respondents are asked to indicate on a five-point Likert scale how frequently they experienced each problem. Response categories for the five-point scale are: &quot;Very often&quot;, &quot;Fairly often&quot;, &quot;Occasionally&quot;, &quot;Hardly ever&quot; and &quot;Never&quot;. The OHIP consists of 14 questions in which higher scores indicate worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of tumor locations of the oral squamous cell cancer</measure>
    <time_frame>Baseline until resection surgery ( approximately 4 weeks)</time_frame>
    <description>Oral squamous cell carcinoma locations acoording to follwoing regions:&#xD;
Anterior compartment which includes lower lip, buccal mucosa, anterior vestibule, anterior ridge and anterior floor mouth&#xD;
Lateral compartment which includes posterior vestibule, posterior alveolar ridge, posterior (lateral) floor of mouth&#xD;
Retromolar compartment which includes alveolar ridge posterior to last molar, region of wisdom teeth, retromolar triangle ie buccal cheek, soft palate (arch), tonsillar regions&#xD;
Tongue which includes ventral tongue (undersurface of tongue), lateral rim of tongue, base of tongue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of tumor staging according to the TNM system</measure>
    <time_frame>Baseline until resection surgery ( approximately 4 weeks)</time_frame>
    <description>Oral squamous cell carcinoma staging according to TNM (Tumor, Node, Metastasis) system.&#xD;
In the TNM system the &quot;T&quot; refers to the size and extent of the main tumor likert from T0 to T4 whereas T0 is the smallest and T4 the biggest size.&#xD;
The main tumor is usually called the primary tumor. The &quot;N&quot; refers to the number of nearby lymph nodes that have cancer likert for N0 to N3 whereas N0 is the single nearby lymphnode and N3 multiple lymphnodes. The &quot;M&quot; refers to whether the cancer has metastasized likert from M0 to M1 whereas M0 is no distant metastasis and M1 is distant metastasis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of surgical duration and hospital stay if resection and reconstruction was performed in one or two stages</measure>
    <time_frame>Day of resection surgery until day of reconstruction surgery up to 18 months</time_frame>
    <description>Duration of surgery (skin to skin) in minutes&#xD;
Length of hospital stay in days&#xD;
Date of osseous reconstruction (if different from resection surgery) in days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of surgical procedures of osseous reconstruction</measure>
    <time_frame>Day of resection surgery until day of reconstruction surgery up to 18 months</time_frame>
    <description>Numers of Bone and soft tissue flaps to reconstruct the mandible: ie number of pieces in which the donor bone(s) is cut to shape the reconstructed mandible&#xD;
Type of bone donor/ bone transfer site(s): Vascularized bone flap(s) or composite flaps (ie bone and adjacent soft tissue harvested within the same flap) and type(s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Different surgical parameters of tumor and segmental mandibular resection if VSP planning was used</measure>
    <time_frame>Day of resection surgery until day of reconstruction surgery up to 18 months</time_frame>
    <description>Use of virtual surgical planning (VSP) for resection: Yes/No.&#xD;
Only virtual planning and simulation of resection (no 3D printing):Yes/No.&#xD;
3D-printed biomodels: Yes/No</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Mandibular Reconstruction</condition>
  <arm_group>
    <arm_group_label>Mandibular Reconstruction</arm_group_label>
    <description>Patients undergoing segmental mandibular defect reconstruction. The decision of one stage or two stage reconstruction is done according to the patient and treating surgeon preferences following the local standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Resection and Reconstruction</intervention_name>
    <description>One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.&#xD;
Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction.</description>
    <arm_group_label>Mandibular Reconstruction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with an acquired segmental mandibular defect secondary to oral squamous&#xD;
        cell carcinoma removal and who require mandibular reconstruction.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Initial pathologically confirmed diagnosis of primary oral squamous cell carcinoma&#xD;
             located in mucosa and/or mandible&#xD;
&#xD;
          -  Undergoing primary curative treatment with segmental resection of the mandible ≥4 cm&#xD;
&#xD;
          -  Intention to undergo mandibular reconstruction with autologous bone using a primary&#xD;
             (one stage) or secondary (two stage) approach&#xD;
&#xD;
          -  Informed consent obtained, ie:&#xD;
&#xD;
               -  Ability to understand the content of the patient information/ICF&#xD;
&#xD;
               -  Willingness and ability to participate in the clinical investigation according to&#xD;
                  the registry plan (RP)&#xD;
&#xD;
               -  Signed and dated IRB/EC approved informed consent (ICF) OR&#xD;
&#xD;
               -  Written consent provided according to the IRB/EC defined and approved procedures&#xD;
                  for patients who are not able to provide to provide independent written informed&#xD;
                  consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors affecting the condyle&#xD;
&#xD;
          -  Distant OSCC metastasis&#xD;
&#xD;
          -  Any other active concomitant malignancy within the last 5 years&#xD;
&#xD;
          -  Patients who require neoadjuvant therapy&#xD;
&#xD;
          -  Patients under palliative care&#xD;
&#xD;
          -  Previous extensive mandibular surgeries (including reconstructions)&#xD;
&#xD;
        Intraoperative exclusion criteria:&#xD;
&#xD;
          -  Nonsegmental mandibular defect (eg. box resection/partial resection)&#xD;
&#xD;
          -  Segmental mandibular defect of less than 4 cm&#xD;
&#xD;
          -  Mandibular defects extending beyond the sigmoid notch into the condyles&#xD;
&#xD;
        Additional exclusion criterion:&#xD;
&#xD;
        • No osseous reconstruction with autologous bone performed within 18 months from resection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rüdiger Zimmerer, PD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joffrey Baczkowski</last_name>
    <phone>+41 44 200 24 31</phone>
    <email>joffrey.baczkowski@aofoundation.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Thomas, PhD</last_name>
    <phone>+ 41 79 671 47 98</phone>
    <email>felix.thomas@aofoundation.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marianne Abouyared, Prof</last_name>
      <phone>916-734-5400</phone>
      <email>mabouyared@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rui Fernandes, Prof</last_name>
      <phone>904-244-3901</phone>
      <email>rui.fernandes@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Schwaiger, MD</last_name>
      <phone>+43 316 385 12428</phone>
      <email>michael.schwaiger@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Ali Modabber, Prof</last_name>
      <phone>+49 241 80 88258</phone>
      <email>amodabber@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Charité</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Max Heiland, Prof</last_name>
      <phone>+49 450 655 270</phone>
      <email>max.heiland@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon Spalthoff, PD, MD</last_name>
      <phone>+49 511 532 4879</phone>
      <email>Spalthoff.Simon@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Rüdiger Zimmerer, PD, MD</last_name>
      <phone>+ 49 341 972 1100</phone>
      <email>ruediger.zimmerer@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenko Slomka, PD, MD</last_name>
      <phone>+49 440054458</phone>
      <email>wenko.smolka@med.lmu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Eppo Wolvius, Prof</last_name>
      <phone>+31 6 22 48 77 81</phone>
      <email>e.wolvius@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical and Surgical Center</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Sergey Epifanov, MD</last_name>
      <phone>+7 (495) 150-11-22</phone>
      <email>mnioi@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Gregorio Sanchez-Ancieto, MD</last_name>
      <phone>+34 913908000</phone>
      <email>gregorio.sanchez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Thor, Prof</last_name>
      <phone>+46 18 6116450</phone>
      <email>andreas.thor@surgsci.uu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Florian Thieringer, MD</last_name>
      <phone>+41 612 657 344</phone>
      <email>Florian.Thieringer@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

